Integrin Alpha V in Urine: A Novel Noninvasive Marker for Prostate Cancer Detection
| Autor: | Marina Y. Zemskova, Maria V. Marinets, Andrey V. Sivkov, Julia V. Pavlova, Andrey N. Shibaev, Konstantin S. Sorokin |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty Urinary system Urology Urine urologic and male genital diseases lcsh:RC254-282 03 medical and health sciences Prostate cancer 0302 clinical medicine Antigen Biopsy Medicine ITGAV Original Research integrin alpha V medicine.diagnostic_test business.industry cancer diagnostic marker Hyperplasia medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens prostate cancer urine 030104 developmental biology Oncology 030220 oncology & carcinogenesis Biomarker (medicine) biomarker business non-invasive cancer screening |
| Zdroj: | Frontiers in Oncology Frontiers in Oncology, Vol 10 (2021) |
| ISSN: | 2234-943X |
| Popis: | Prostate cancer (PCa) diagnosis based on patient urine analysis provides non-invasive and promising method as compared to biopsy and a prostate-specific antigen (PSA) test. This study was conceived to investigate whether Integrin alpha V (ITGAV) protein is present in urine and assess the urinary ITGAV diagnostic potential for PCa. Materials and Methods: Urinary ITGAV expression was determined by Western blot analysis and quantified by ELISA in urine from men with PCa (n = 47), benign prostate hyperplasia (n = 42) and age-matched controls (n = 22). Results: The level of ITGAV protein was significantly lower in PCa urine samples as compared to those in the control group (p < 0.00001). The decrease of ITGAV in urine was highly predictive of PCa with 91.5% sensitivity, 91.4% specificity, 0.93 area under the ROC curve, and its specificity was better than that of serum PSA. Conclusion: Urinary ITGAV provides a novel noninvasive biomarker with high specificity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|